** Drug developer BioAge Labs' BIOA.O shares rise ~10% to $4.52
** BIOA says it is collaborating with Swiss drugmaker Novartis NOVN.S to find new drug targets for age-related diseases
** BIOA will receive $20 mln upfront and up to $530 mln in milestone payments
** Including session's moves, stock down 80% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。